Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 study of BBT-015 in healthy human subjects.

Trial Profile

Phase 1 study of BBT-015 in healthy human subjects.

Phase of Trial: Phase I

Latest Information Update: 04 May 2018

At a glance

  • Drugs BBT-015 (Primary) ; Pegfilgrastim
  • Indications Acute radiation syndrome; Neutropenia
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 04 May 2018 Status changed from recruiting to completed, according to a Bolder BioTechnology media release.
    • 27 Apr 2018 Results presented in a Bolder BioTechnology Media Release.
    • 08 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top